Drug · CHEMBL995
LOSARTAN POTASSIUM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LOSARTAN POTASSIUM. Drugs and targets, record CHEMBL995. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL995
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Aradois, DU PONT-753, DUP 753, DUP-753, DUP753, E-3340, L-158086, Losacar, Losartan monopotassium salt, Losata, MK-0954, MK0954, Nu-lotan, Presartan-50, Tancin, Zaart
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | Type-1 angiotensin II receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/185 |
Source ChEMBL
Diseases18
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hypertensive disorder | Approval | DailyMed and PMDA | 100 | 16 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| essential hypertension | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0001134 |
| eosinophilic esophagitis | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005361 |
| Proteinuria | Approval | DailyMed and PMDA | 5 | 1 | https://conductscience.org/library/drugs?q=HP_0000093 |
| chronic kidney disease | Approval | DailyMed | 3 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005300 |
| Hypertension resistant to conventional therapy | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0430034 |
| keloid | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005348 |
| malignant pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| metabolic syndrome | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0000195 |
| non-alcoholic fatty liver | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_1001248 |
1 to 10 of 18Source Open Targets
See all 18 diseasesTrials55
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00546052 | A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331) | Phase 3 | 1,738 | 2009-06-23 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00739674 | SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335) | Phase 3 | 992 | 2010-08-11 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00949884 | Olmesartan Comparison to Losartan in Hypertensive Subjects | Phase 4 | 941 | 2011-02-28 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00546754 | BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) | Phase 3 | 808 | 2010-04-13 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00882440 | A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011) | Phase 3 | 576 | 2009-06-10 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00887250 | A Study to Investigate the Antihypertensive Efficacy of MK0954 | Phase 3 | 366 | 2009-06-24 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT01307046 | MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) | Phase 3 | 336 | 2013-03-22 | MK-0954A | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01302691 | MK-0954E Study in Participants With Hypertension (MK-0954E-357) | Phase 3 | 327 | 2017-01-27 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00496834 | LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED) | Phase 4 | 201 | 2010-12-15 | losartan potassium | Its name | ClinicalTrials.gov |
| NCT00886600 | A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED) | Phase 3 | 122 | 2009-07-14 | losartan potassium | Its name | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Losartan-Based Regimen Alone (L Group) vs Diet Management and Losartan-Based Regimen (DML Group): serious adverse events | 13 of 531 | 10 of 453 | 984 | NCT00739674 | Trial comparisons |
| Losartan 50 mg/HCTZ 12.5 mg vs Valsartan 80 mg/HCTZ 12.5 mg: serious adverse events | 11 of 425 | 5 of 383 | 808 | NCT00546754 | Trial comparisons |
| L50/H12.5/A5 vs L50 + A5: serious adverse events | 1 of 164 | 1 of 163 | 327 | NCT01302691 | Trial comparisons |
| Losartan vs Carvedilol: serious adverse events | 5 of 101 | 6 of 100 | 201 | NCT00496834 | Trial comparisons |
| Losartan/HCTZ (Test) vs Hyzaar® (Reference): serious adverse events | 0 of 80 | 0 of 80 | 160 | NCT01149473 | Trial comparisons |
| Losartan vs Placebo: deaths from any cause | 0 of 43 | 0 of 40 | 83 | NCT03467217 | Trial comparisons |
| Losartan vs Placebo: serious adverse events | 0 of 43 | 4 of 40 | 83 | NCT03467217 | Trial comparisons |
| Losartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ Capsule vs Losartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet: serious adverse events | 0 of 38 | 0 of 39 | 77 | NCT00953680 | Trial comparisons |
| Losartan/HCTZ (Test) vs Hyzaar® (Reference): serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT01149486 | Trial comparisons |
| Losartan vs Placebo: deaths from any cause | 0 of 11 | 0 of 11 | 22 | NCT04632589 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials33
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Ball-Toss Game | 1 | 0 | ConductCognition |
| Task Switching Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL995
GET https://conductscience.org/api/drugs/v1/CHEMBL995/trials?page=2